[Inflammatory cancer of the breast: review and experience at Saint-Louis hospital].
Inflammatory breast cancer represents about 1 to 6% of all breast cancers. It has a sudden onset and affects women of the same age as other breast cancers. Its particular feature is the almost constant development of metastases. The 5-year survival after surgery or surgery and radiotherapy varies between 0 and 28% with a median survival of 18 months. The use of anthracycline-based chemotherapy has doubled the median survival, but has not achieved cure. Clinical research is directed towards therapeutic intensification with or without autologous bone marrow transplantation. The authors report their experience at Hôpital Saint-Louis.
Espié
M
M
Service d'Oncologie Médicale, Hôpital Saint-Louis, Paris.
Extra
J M
JM
de Roquancourt
A
A
Bourstyn
E
E
Hennequin
C
C
Morvan
F
F
Marty
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D005602:France; D006757:Hospital Units; D006801:Humans; D008327:Mammography; D008875:Middle Aged; D011379:Prognosis; D016217:Ultrasonography, Mammary
Cancer du sein inflammatoire: revue et expérience de l'Hôpital Saint-Louis.